Literature DB >> 24400425

Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry: rapid identification of bacteria isolated from patients with cystic fibrosis.

S Baillie1, K Ireland1, S Warwick2, D Wareham1, M Wilks1.   

Abstract

Despite extensive research into the diagnosis and management of cystic fibrosis (CF) over the past decades, sufferers still have a median life expectancy of less than 37 years. Respiratory tract infections have a significant role in increasing the morbidity and mortality of patients with CF via a progressive decline in lung function. Rapid identification of organisms recovered from CF sputum is necessary for effective management of respiratory tract infections; however, standard techniques of identification are slow, technically demanding and expensive. The aim of this study is to asses the suitability of matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) in identifying bacteria isolated from the respiratory tract of patients with CF, and is assessed by testing the accuracy of MALDI-TOF MS in identifying samples from a reference collection of rare CF strains in conjunction with comparing MALDI-TOF MS and standard techniques in identifying clinical isolates from sputum samples of CF patients. MALDI-TOF MS accurately identified 100% of isolates from the reference collection of rare CF pathogens (EuroCare CF collection). The isolate identification given by MALDI-TOF MS agreed with that given by standard techniques for 479/481 (99.6%) clinical isolates obtained from respiratory samples provided by patients with CE In two (0.4%) of 481 samples there was a discrepancy in identification between MALDI-TOF MS and standard techniques. One organism was identified as Pseudomonas aeruginosa by MALDI-TOF but could only be identified by the laboratory's standard methods as of the Pseudomonas genus. The second organism was identified as P. beteli by MALDI-TOF MS and Stenotrophomonas maltophilia by standard methods. This study shows that MALDI-TOF MS is superior to standard techniques in providing cheap, rapid and accurate identification of CF sputum isolates.

Entities:  

Mesh:

Year:  2013        PMID: 24400425     DOI: 10.1080/09674845.2013.11669948

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  5 in total

1.  A commentary on the role of molecular technology and automation in clinical diagnostics.

Authors:  Ciara O'Connor; Marie Fitzgibbon; James Powell; Denis Barron; Jim O'Mahony; Lorraine Power; Nuala H O'Connell; Colum Dunne
Journal:  Bioengineered       Date:  2014-03-21       Impact factor: 3.269

2.  Identification of Rare Bacterial Pathogens by 16S rRNA Gene Sequencing and MALDI-TOF MS.

Authors:  Percy Schröttner; Florian Gunzer; Jana Schüppel; Wolfram W Rudolph
Journal:  J Vis Exp       Date:  2016-07-11       Impact factor: 1.355

3.  Impact of gram negative bacteria airway recolonization on the occurrence of chronic lung allograft dysfunction after lung transplantation in a population of cystic fibrosis patients.

Authors:  Sarah Orfanos; Carine Gomez; Sophie Baron; Ritesh Akkisetty; Nadine Dufeu; Bérengère Coltey; Pascal Alexandre Thomas; Jean Marc Rolain; Martine Reynaud-Gaubert
Journal:  BMC Microbiol       Date:  2018-08-20       Impact factor: 3.605

4.  Matrix-assisted laser desorption/ionization time-of-flight MS for the accurate identification of Burkholderia cepacia complex and Burkholderia gladioli in the clinical microbiology laboratory.

Authors:  Kendrew S K Wong; Suk Dhaliwal; Jennifer Bilawka; Jocelyn A Srigley; Sylvie Champagne; Marc G Romney; Peter Tilley; Manish Sadarangani; James E A Zlosnik; Mark A Chilvers
Journal:  J Med Microbiol       Date:  2020-06-29       Impact factor: 2.472

Review 5.  MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis.

Authors:  Neelja Singhal; Manish Kumar; Pawan K Kanaujia; Jugsharan S Virdi
Journal:  Front Microbiol       Date:  2015-08-05       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.